EMA Authorised: Seffalair Spiromax (fluticasone propionate;salmeterol xinafoate) — Teva B.V.

View source ↗

Summary

The EMA has authorised Seffalair Spiromax, a fixed-dose inhaler containing fluticasone propionate and salmeterol xinafoate, for asthma; Teva B.V. is the marketi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Seffalair Spiromax (fluticasone propionate; salmeterol xinafoate)

Snippet

Status: Authorised. Therapeutic area: Asthma. MAH: Teva B.V.. Decision date: 12/12/2025